# Compass Therapeutics to Participate in Upcoming June Investor Events
Canonical URL: https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840
Ticker: CMPX
Company: Compass Therapeutics
Source: Compass Therapeutics
Published: 2026-05-28 11:30 EST
## Summary

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

## Article Body
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.

Details are as follows:

Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 8:45 AM ET Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference Date: Tuesday, June 9, 2026 Time: 8:00 AM ET Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com .

Investor Contact ir@compasstherapeutics.com

Media Contact Anna Gifford, Chief of Staff media@compasstherapeutics.com 617-500-8099
## Recent Company News
- 2026-07-17 14:42 EST — [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60) — Source: Compass Therapeutics
- 2026-05-28 11:30 EST — [Compass Therapeutics to Participate in Upcoming June Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840) — Source: Compass Therapeutics
- 2026-05-21 21:00 EST — [Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911) — Source: Compass Therapeutics
- 2026-05-12 11:30 EST — [Compass Therapeutics to Participate in Upcoming May Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121) — Source: Compass Therapeutics
- 2026-05-05 11:30 EST — [Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-c-7bfdf19a) — Source: Compass Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)